Literature DB >> 11961171

Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study.

K Waterloo1, R Omdal, G Husby, S I Mellgren.   

Abstract

OBJECTIVE: To evaluate potential changes in cognitive functions over a 5-yr period in patients with systemic lupus erythematosus (SLE).
METHODS: Twenty-eight patients with SLE were examined at baseline and after a mean follow-up of 60.7+/-5.0 months using standardized neuropsychological tests. Group changes in performance over time were measured and the effects of baseline values for subsequent changes in individual variables after 5 yr were evaluated.
RESULTS: When all SLE patients were considered as a group, seven out of nine (78%) neuropsychological variables remained unchanged and two (22%) improved significantly during the observation period, possibly due to methodological bias. Analysis of the importance of the level of initial cognitive performance for subsequent changes during the observation period, demonstrated that cognitive changes were not significantly influenced by baseline levels, except for a trend in three of nine variables. Neither demographic nor disease-associated quantitative factors were associated with cognitive changes over time.
CONCLUSION: Cognitive dysfunction seems to be a relatively stable feature of central nervous system involvement in SLE. A decrease in performance over time was not demonstrated consistently in the majority of domains.

Entities:  

Mesh:

Year:  2002        PMID: 11961171     DOI: 10.1093/rheumatology/41.4.411

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

1.  Human lupus autoantibodies against NMDA receptors mediate cognitive impairment.

Authors:  Czeslawa Kowal; Lorraine A Degiorgio; Ji Y Lee; Mark A Edgar; Patricio T Huerta; Bruce T Volpe; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-14       Impact factor: 11.205

Review 2.  Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus.

Authors:  Meggan Mackay
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 3.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

4.  Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes.

Authors:  Elizabeth Kozora; Sterling G West; Steven F Maier; Christopher M Filley; David B Arciniegas; Mark Brown; David Miller; Alex Grimm; Lening Zhang
Journal:  J Neurol Sci       Date:  2010-05-23       Impact factor: 3.181

Review 5.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 6.  Systemic lupus erythematosus, the brain, and anti-NR2 antibodies.

Authors:  Maria B Lauvsnes; Roald Omdal
Journal:  J Neurol       Date:  2011-09-10       Impact factor: 4.849

7.  Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; D Isenberg; A Rahman; G S Alarcón; D D Gladman; P R Fortin; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; E Ginzler; I N Bruce; K Steinsson; M Khamashta; M Petri; S Manzi; M A Dooley; R Ramsey-Goldman; R Van Vollenhoven; O Nived; G Sturfelt; C Aranow; K Kalunian; M Ramos-Casals; A Zoma; J Douglas; K Thompson; V Farewell
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

Review 8.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 9.  Systemic lupus erythematosus involving the nervous system: presentation, pathogenesis, and management.

Authors:  Julia J Rhiannon
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 10.  Neuropsychiatric disease in collagen vascular diseases and vasculitis.

Authors:  Peter Berlit
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.